CliffBio
biologic

Sogroya

somapacitan-beco

Loss of exclusivityApril 2035projected — 12-year biologic exclusivity estimate
CompanyNovo Nordisk Inc.

Drug detail

Brand nameSogroya
Active ingredientsomapacitan-beco
Strength15MG/1.5ML (10MG/ML)
Dosage formInjection
RouteSubcutaneous
ModalityBiologic
FDA approvalApril 2023
Marketing statusRx

More from Novo Nordisk Inc.

Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the projected — 12-year biologic exclusivity estimate; estimates are projections, not legal advice.

Sogroya patent cliff — loss of exclusivity April 2035 | CliffBio